Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit

Chinese Journal of Cancer

Volumn 31, Issue 7, 2012, Pages 319-326

  Johnson, Daniel E ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

ABT 737; Bcl XL; Cetuximab; EGFR; STAT3; STAT3 decoy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; METHOTREXATE; NIMOTUZUMAB; PANITUMUMAB; PROTEIN BCL XL; STAT3 PROTEIN; ZALUTUMUMAB;

AUTOPHOSPHORYLATION; BIOCHEMISTRY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL MOTILITY; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; CELL PROLIFERATION; HEAD AND NECK NEOPLASMS; HUMANS; NITROPHENOLS; PIPERAZINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SULFONAMIDES;

EID: 84864380098     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.011.10404     Document Type: Review

References (92)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009,59:225-249.
2. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst, 2007,99:777-789.
3. Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev, 2009,18:541-550.
4. Fung C, Grandis JR. Emerging drugs to treat squamous cell carcinomas of the head and neck. Expert Opin Emerg Drugs, 2010,15:355-373.
5. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-ce ll carcinoma of the head and neck. N Engl J Med, 2001,344:1125-1131.
6. Herrero R, Castellsagué X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst, 2003,95:1772-1783.
7. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst, 2000,92:709-720.
8. Hammarstedt L, Lindquist D, Dahlstrand H, et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer, 2006,119:2620-2623.
9. Chaturvedi AK, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-re lated and-un related oral squamous cell carcinomas in the United States. J Clin Oncol, 2008,26:612-619.
10. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer, 2005,103:1843-1849.
11. Gillison ML, D'Souza G, Westra W, et al. Distinct risk factor profiles for human papillomavirus type 16-po sitive and human papillomavirus type 16-ne gative head and neck cancers. J Natl Cancer Inst, 2008,100:407-420.
12. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-po sitive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst, 2008,100:261-269.
13. Licitra L, Perrone F, Bossi P, et al. High-ris k human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol, 2006,24:5630-5636.
14. Gillison ML. Human papillomavirus-as sociated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol, 2004,31:744-754.
15. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med, 2008,359:1143-1154.
16. Argiris A, Karamouzis MV, Raben D, et al. Head and neck cancer. Lancet, 2008,371:1695-1709.
17. Gibson MK, Forastiere AA. Reassessment of the role of induction chemotherapy for head and neck cancer. Lancet Oncol, 2006,7:565-574.
18. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther, 2004,102:37-46.
19. Lurje G, Lenz HJ. EGFR signaling and drug discovery. Oncology, 2009,77:400-410.
20. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res, 1993,53:3579-3584.
21. Rubin Grandis J, Zeng Q, Tweardy DJ. Retinoic acid normalizes the increased gene transcription rate of TGF-al pha and EGFR in head and neck cancer cell lines. Nat Med, 1996,2:237-240.
22. Sheu JJ, Hua CH, Wan L, et al. Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res, 2009,69:2568-2576.
23. Rubin Grandis J, Melhem MF, Gooding WE, et al. Levels of TGF-al pha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst, 1998,90: 824-832.
24. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res, 2006,12:5064-5073.
25. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol, 2006,24:2666-2672.
26. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-ce ll carcinoma of the head and neck. N Engl J Med, 2006,354:567-578.
27. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-ye ar survival data from a phase 3 randomised trial, and relation between cetuximab-in duced rash and survival. Lancet Oncol, 2010,11:21-28.
28. Vermorken JB, Mesia R, Rivera F, et al. Platinum-ba sed chemotherapy plus cetuximab in head and neck cancer. N Engl J Med, 2008,359:1116-1127.
29. Rivera F, Garcia-Castano A, Vega N, et al. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther, 2009,9:1421-1428.
30. Mesia R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-ba sed chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol, 2010,21:1967-1973.
31. Rivera F, Vega-Villegas ME, Lopez-Brea MF, et al. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol, 2008,47:9-19.
32. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/ overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A, 2003,100:639-644.
33. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A, 2007,104:4071-4076.
34. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol, 2009,27:1864-1871.
35. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-co ntrolled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol, 2009,27:5s. abstract 6011.
36. Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, et al. Tyrosine kinase inhibitors-small molecular weight compounds inhibiting EGFR. Curr Opin Mol Ther, 2009,11: 308-321.
37. Xia W, Lau YK, Zhang HZ, et al. Strong correlation between c-er bB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res, 1997,3:3-9.
38. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res, 1999,5:4164-4174.
39. Ekberg T, Nestor M, Engstrom M, et al. Expression of EGFR, HER2, HER3, and HER4 in metastatic squamous cell carcinomas of the oral cavity and base of tongue. Int J Oncol, 2005,26:1177-1185.
40. Cavalot A, Martone T, Roggero N, et al. Prognostic impact of HER-2/ neu expression on squamous head and neck carcinomas. Head Neck, 2007,29:655-664.
41. Shao H, Cheng HY, Cook RG, et al. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res, 2003,63:3923-3930.
42. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res, 2002,8:945-954.
43. Darnell JE Jr. STATs and gene regulation. Science, 1997,277: 1630-1635.
44. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 2000,19:2468-2473.
45. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell, 1999,98:295-303.
46. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-m ediated cell growth in vitro. J Clin Invest, 1998,102: 1385-1392.
47. Grandis JR, Drenning SD, Zeng Q, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A, 2000,97: 4227-4232.
48. Sriuranpong V, Park JI, Amornphimoltham P, et al. Epidermal growth factor receptor-in dependent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res, 2003,63:2948-2956.
49. Xi S, Zhang Q, Dyer KF, et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem, 2003,278:31574-31583.
50. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res, 2002,62:3351-3355.
51. Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing-m ediated oral carcinogenesis. Cancer, 2002,94:2393-2400.
52. Shah NG, Trivedi TI, Tankshali RA, et al. Stat3 expression in oral squamous cell carcinoma: association with clinicopatho-logical parameters and survival. Int J Biol Markers, 2006,21: 175-183.
53. Weber A, Hengge UR, Stricker I, et al. Protein microarrays for the detection of biomarkers in head and neck squamous cell carcinomas. Hum Pathol, 2007,38:228-238.
54. Arany I, Chen SH, Megyesi JK, et al. Differentiation-de pendent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck. Cancer Lett, 2003,199:83-89.
55. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A, 2003,100:4138-4143.
56. Gao LF, Xu DQ, Wen LJ, et al. Inhibition of STAT3 expression by siRNA suppresses growth and induces apoptosis in laryngeal cancer cells. Acta Pharmacol Sin, 2005,26:377-383.
57. Gao LF, Wen LJ, Yu H, et al. Knockdown of Stat3 expression using RNAi inhibits growth of laryngeal tumors in vivo. Acta Pharmacol Sin, 2006,27:347-352.
58. Masuda M, Wakasaki T, Suzui M, et al. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers? Curr Cancer Drug Targets, 2010,10:117-126.
59. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene, 2005,24:970-979.
60. Takeda K, Noguchi K, Shi W, et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A, 1997,94:3801-3804.
61. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-ne gative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res, 1999,59:5059-5063.
62. Sano S, Itami S, Takeda K, et al. Keratinocyte-sp ecific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J, 1999,18:4657-4668.
63. Takeda K, Akira S. Multi-fu nctional roles of Stat3 revealed by conditional gene targeting. Arch Immunol Ther Exp (Warsz), 2001,49:279-83.
64. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res, 2005,65:5828-5834.
65. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett, 2007,251:199-210.
66. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-m ediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem, 2001,276:45443-45455.
67. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther, 2004,3: 261-269.
68. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-ba sed virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A, 2007,104:7391-7396.
69. Song H, Wang R, Wang S, et al. A low-m olecular-w eight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci U S A, 2005,102:4700-4705.
70. Schust J, Sperl B, Hollis A, et al. Stattic: a small-m olecule inhibitor of STAT3 activation and dimerization. Chem Biol, 2006,13:1235-1242.
71. Kim ES, Hong SY, Lee HK, et al. Guggulsterone inhibits angiogenesis by blocking STAT3 and VEGF expression in colon cancer cells. Oncol Rep, 2008,20:1321-1327.
72. Ahn KS, Sethi G, Sung B, et al. Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1. Cancer Res, 2008,68:4406-4415.
73. Hellsten R, Johansson M, Dahlman A, et al. Galiellalactone is a novel therapeutic candidate against hormone-re fractory prostate cancer expressing activated Stat3. Prostate, 2008,68:269-280.
74. Bhutani M, Pathak AK, Nair AS, et al. Capsaicin is a novel blocker of constitutive and interleukin-6-in ducible STAT3 activation. Clin Cancer Res, 2007,13:3024-3032.
75. Blaskovich MA, Sun J, Cantor A, et al. Discovery of JSI-12 4 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res, 2003,63:1270-1279.
76. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloyl-methane) inhibits constitutive and IL-6-in ducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol, 2003,171:3863-3871.
77. Pathak AK, Bhutani M, Nair AS, et al. Ursolic acid inhibits STAT3 activation pathway leading to suppression of proliferation and chemosensitization of human multiple myeloma cells. Mol Cancer Res, 2007,5:943-955.
78. Leeman RJ, Lui VW, Grandis JR. STAT3 as a therapeutic target in head and neck cancer. Expert Opin Biol Ther, 2006,6: 231-241.
79. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 1999,10:105-115.
80. Drenning SD, Marcovitch AJ, Johnson DE, et al. Bcl-2 but not Bax expression is associated with apoptosis in normal and transformed squamous epithelium. Clin Cancer Res, 1998,4: 2913-2921.
81. Trask DK, Wolf GT, Bradford CR, et al. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation. Laryngoscope, 2002,112:638-644.
82. Pena JC, Thompson CB, Recant W, et al. Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer, 1999,85:164-170.
83. Homma A, Furuta Y, Oridate N, et al. Prognostic significance of clinical parameters and biological markers in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiotherapy. Clin Cancer Res, 1999,5:801-806.
84. Sharma H, Sen S, Lo Muzio L, et al. Antisense-m ediated downregulation of anti-ap optotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol Ther, 2005,4:720-727.
85. Shangary S, Johnson DE. Peptides derived from BH3 domains of Bcl-2 family members: a comparative analysis of inhibition of Bcl-2, Bcl-x(L) and Bax oligomerization, induction of cytochrome c release, and activation of cell death. Biochemistry, 2002,41: 9485-9495.
86. Li R, Boehm AL, Miranda MB, et al. Targeting antiapoptotic Bcl-2 family members with cell-pe rmeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells. Neoplasia, 2007,9:801-811.
87. Bauer JA, Trask DK, Kumar B, et al. Reversal of cisplatin resistance with a BH3 mimetic, (-)-go ssypol, in head and neck cancer cells: role of wild-ty pe p53 and Bcl-xL. Mol Cancer Ther, 2005,4:1096-1104.
88. Oliver CL, Bauer JA, Wolter KG, et al. In vitro effects of the BH3 mimetic, (-)-go ssypol, on head and neck squamous cell carcinoma cells. Clin Cancer Res, 2004,10:7757-7763.
89. Wolter KG, Wang SJ, Henson BS, et al. (-)-go ssypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia, 2006,8:163-172.
90. Oltersdorf T, Elmore SW, Shoemaker AR, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 2005,435:677-681.
91. Li R, Zang Y, Li C, et al. ABT-73 7 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-m ediated pathway. Mol Pharmacol, 2009,75: 1231-1239.
92. Tse C, Shoemaker AR, Adickes J, et al. ABT-26 3: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res, 2008,68:3421-3428.